Fact Sheet: HIV Drug Resistance - ISS-G20 Laboratorium Repository

• At the end of 2021, 28.7 million people were receiving antiretroviral therapy worldwide. HIV drug resistance can compromise the effectiveness of antiretroviral drugs in reducing HIV incidence and HIV-associated morbidity and mortality.
• In 21 of 30 surveys reported to WHO, pretreatment HIV drug resistance to nevirapine (NVP) or efavirenz (EFV) in populations initiating first-line ART reached levels above 10%.
• Pretreatment HIV drug resistance to the non-nucleoside reverse transcriptase inhibitors (NNRTI) drug class is up to 3 times more common in people with previous exposure to antiretroviral drugs.
• Nearly one half of infants born to mothers infected with HIV has HIV drug resistance to one or more NNRTIs.
• Global prevalence of resistance to the NNRTI drug class emphasizes the need to fast-track the transition to the newer dolutegravir-based regimens.
• To stop HIV drug resistance all global stakeholders should promote the availability of optimal medicines to treat HIV infections, support retention in care and optimal adherence to treatment, increase access and use of viral load testing to know if HIV treatment is working, and rapidly switch regimens in cases of confirmed treatment failure.

Entire content available on: https://www.who.int/news-room/fact-sheets/detail/hiv-drug-resistance